急性呼吸衰竭接受有创机械通气患者的阿片类药物给药实践模式
该回顾性队列研究纳入Kaiser Permanente Northern California(KPNC)21家医院的13,140例和Philips电子ICU研究机构(eRI)96家医院的52,033例急性呼吸衰竭并启动有创机械通气的患者,评估阿片输注使用及剂量。结果显示,机械通气21天内接受阿片输注者KPNC为7,023例(53.4%)、eRI为16,311例(31.1%);校正患者和医院固定效应后,医院因素分别解释两队列阿片输注使用变异的7%(95%CI 3-11%)和39%(95%CI 28-49%)。接受阿片输注者中,中位每日芬太尼当量剂量KPNC为692 µg(IQR 129-1341 µg),eRI为200 µg(IQR 0-1050 µg);医院因素解释剂量变异的4%(95%CI 1-7%)和20%(95%CI 15-26%)。作者认为,机械通气伴随可观阿片暴露,可能存在镇痛不足或过度治疗,结果可用于医院镇痛实践基准比较及镇痛镇静临床试验的常规护理对照。
要点
- KPNC队列13,140例中7,023例(53.4%)在机械通气21天内接受阿片输注;eRI队列52,033例中16,311例(31.1%)接受阿片输注。
- 校正患者和医院固定效应后,医院因素解释阿片输注使用变异的比例:KPNC 7%(95%CI 3-11%),eRI 39%(95%CI 28-49%)。
- 接受阿片输注者中位每日芬太尼当量剂量:KPNC 692 µg(IQR 129-1341 µg),eRI 200 µg(IQR 0-1050 µg)。
- 医院因素解释中位每日芬太尼当量剂量变异的比例:KPNC 4%(95%CI 1-7%),eRI 20%(95%CI 15-26%)。
- 作者认为机械通气伴随可观阿片暴露,提示可能存在镇痛不足或过度治疗,结果可用于医院镇痛实践基准比较。
适用人群与场景
- 诊断为急性呼吸衰竭并启动有创机械通气的患者,来自KPNC的21家医院(13,140例)和eRI的96家医院(52,033例)。
研究设计与关键结果
- 回顾性队列研究,纳入KPNC 21家医院13,140例和eRI 96家医院52,033例急性呼吸衰竭并启动有创机械通气的患者。
- 机械通气前21天内接受阿片输注:KPNC 7,023例(53.4%),eRI 16,311例(31.1%)。
- 校正患者和医院固定效应后,医院因素解释阿片输注使用变异的比例:KPNC 7%(95%CI 3-11%),eRI 39%(95%CI 28-49%)。
- 接受阿片输注者中位每日芬太尼当量剂量:KPNC 692 µg(IQR 129-1341 µg),eRI 200 µg(IQR 0-1050 µg)。
- 医院因素解释中位每日芬太尼当量剂量变异的比例:KPNC 4%(95%CI 1-7%),eRI 20%(95%CI 15-26%)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研究结果可用于医院镇痛实践与风险校正均值的基准比较,并可用于 informing 镇痛和镇静临床试验的常规护理对照臂。
- 作者认为,机械通气伴随可观阿片暴露,研究结果提示可能存在镇痛不足或过度治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The opioid crisis is impacting people across the country and deserves attention to be able to curb the rise in opioid-related deaths.
OBJECTIVES: To evaluate practice patterns in opioid infusion administration and dosing for patients with acute respiratory failure receiving invasive mechanical ventilation.
DESIGN: Retrospective cohort study.
SETTING AND PARTICIPANTS: Patients from 21 hospitals in Kaiser Permanente Northern California and 96 hospitals in Philips electronic ICU Research Institute.
MAIN OUTCOMES AND MEASURES: We assessed whether patients received opioid infusion and the dose of said opioid infusion.
RESULTS: We identified patients with a diagnosis of acute respiratory failure who were initiated on invasive mechanical ventilation. From each patient, we determined if opioid infusions were administered and, among those who received an opioid infusion, the median daily dose of fentanyl infusion. We used hierarchical regression models to quantify variation in opioid infusion use and the median daily dose of fentanyl equivalents across hospitals. We included 13,140 patients in the KPNC cohort and 52,033 patients in the eRI cohort. A total of 7,023 (53.4%) and 16,311 (31.1%) patients received an opioid infusion in the first 21 days of mechanical ventilation in the KPNC and eRI cohorts, respectively. After accounting for patient- and hospital-level fixed effects, the hospital that a patient was admitted to explained 7% (95% CI, 3-11%) and 39% (95% CI, 28-49%) of the variation in opioid infusion use in the KPNC and eRI cohorts, respectively. Among patients who received an opioid infusion, the median daily fentanyl equivalent dose was 692 µg (interquartile range [IQR], 129-1341 µg) in the KPNC cohort and 200 µg (IQR, 0-1050 µg) in the eRI cohort. Hospital explained 4% (95% CI, 1-7%) and 20% (95% CI, 15-26%) of the variation in median daily fentanyl equivalent dose in the KPNC and eRI cohorts, respectively.
CONCLUSIONS AND RELEVANCE: In the context of efforts to limit healthcare-associated opioid exposure, our findings highlight the considerable opioid exposure that accompanies mechanical ventilation and suggest potential under and over-treatment with analgesia. Our results facilitate benchmarking of hospitals' analgesia practices against risk-adjusted averages and can be used to inform usual care control arms of analgesia and sedation clinical trials.
参考来源
- Myers LC, Bosch NA, Soltesz L, et al. Opioid Administration Practice Patterns in Patients With Acute Respiratory Failure Who Undergo Invasive Mechanical Ventilation. Crit Care Explor. 2024. PMID: 39018285. doi:10.1097/CCE.0000000000001123
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。